000144725 001__ 144725
000144725 005__ 20240906111328.0
000144725 0247_ $$2doi$$a10.1080/2162402X.2024.2379062
000144725 0248_ $$2sideral$$a139541
000144725 037__ $$aART-2024-139541
000144725 041__ $$aeng
000144725 100__ $$aPesini, Cecilia
000144725 245__ $$aIn-depth analysis of the interplay between oncogenic mutations and NK cell-mediated cancer surveillance in solid tumors
000144725 260__ $$c2024
000144725 5060_ $$aAccess copy available to the general public$$fUnrestricted
000144725 5203_ $$aNatural killer (NK) cells play a crucial role in antitumoral and antiviral responses. Yet, cancer cells can alter themselves or the microenvironment through the secretion of cytokines or other factors, hindering NK cell activation and promoting a less cytotoxic phenotype. These resistance mechanisms, often referred to as the “hallmarks of cancer” are significantly influenced by the activation of oncogenes, impacting most, if not all, of the described hallmarks. Along with oncogenes, other types of genes, the tumor suppressor genes are frequently mutated or modified during cancer. Traditionally, these genes have been associated with uncontrollable tumor growth and apoptosis resistance. Recent evidence suggests oncogenic mutations extend beyond modulating cell death/proliferation programs, influencing cancer immunosurveillance. While T cells have been more studied, the results obtained highlight NK cells as emerging key protagonists for enhancing tumor cell elimination by modulating oncogenic activity. A few recent studies highlight the crucial role of oncogenic mutations in NK cell-mediated cancer recognition, impacting angiogenesis, stress ligands, and signaling balance within the tumor microenvironment. This review will critically examine recent discoveries correlating oncogenic mutations to NK cell-mediated cancer immunosurveillance, a relatively underexplored area, particularly in the era dominated by immune checkpoint inhibitors and CAR-T cells. Building on these insights, we will explore opportunities to improve NK cell-based immunotherapies, which are increasingly recognized as promising alternatives for treating low-antigenic tumors, offering significant advantages in terms of safety and manufacturing suitability.
000144725 536__ $$9info:eu-repo/grantAgreement/ES/AEI/PID2020-113963RB-I00$$9info:eu-repo/grantAgreement/ES/AEI/RYC2022-036627-I$$9info:eu-repo/grantAgreement/ES/DGA/B29-23R$$9info:eu-repo/grantAgreement/ES/ISCIII/CB21-13-00087$$9info:eu-repo/grantAgreement/ES/MICINN/PID2022-136554OA-I00
000144725 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/
000144725 655_4 $$ainfo:eu-repo/semantics/review$$vinfo:eu-repo/semantics/publishedVersion
000144725 700__ $$aArtal, Laura
000144725 700__ $$aPaúl Bernal, Jorge
000144725 700__ $$aSánchez Martinez, Diego
000144725 700__ $$0(orcid)0000-0003-0154-0730$$aPardo, Julián$$uUniversidad de Zaragoza
000144725 700__ $$0(orcid)0000-0002-3888-7036$$aRamírez-Labrada, Ariel
000144725 7102_ $$11011$$2566$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Inmunología
000144725 773__ $$g13, 1 (2024), [22 pp.]$$pOncoimmunology$$tOncoImmunology$$x2162-4011
000144725 8564_ $$s3178849$$uhttps://zaguan.unizar.es/record/144725/files/texto_completo.pdf$$yVersión publicada
000144725 8564_ $$s3363920$$uhttps://zaguan.unizar.es/record/144725/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000144725 909CO $$ooai:zaguan.unizar.es:144725$$particulos$$pdriver
000144725 951__ $$a2024-09-06-10:24:50
000144725 980__ $$aARTICLE